Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Post Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the Prevention of COVID-19, a Myth or a Reality? The PEP-CQ Study

Dhibar et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106224, NCT04408456
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Symp. case 44% Improvement Relative Risk Case, PCR+ 50% Case 41% HCQ for COVID-19  Dhibar et al.  Prophylaxis Is post-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 317 patients in India Fewer cases with HCQ (p=0.041) c19hcq.org Dhibar et al., Int. J. Antimicrobial A.., Nov 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Low dose prospective PEP study with 132 HCQ patients and 185 control patients, showing significantly lower COVID-19 cases with treatment. There were no serious adverse events. HCQ 800mg on day one followed by 400mg once weekly for 3 weeks.
risk of symptomatic case, 43.9% lower, RR 0.56, p = 0.21, treatment 6 of 132 (4.5%), control 15 of 185 (8.1%), NNT 28, adjusted per study.
risk of case, 50.0% lower, RR 0.50, p = 0.04, treatment 10 of 132 (7.6%), control 28 of 185 (15.1%), NNT 13, adjusted per study, PCR+.
risk of case, 41.0% lower, RR 0.59, p = 0.03, treatment 14 of 132 (10.6%), control 36 of 185 (19.5%), NNT 11, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Dhibar et al., 6 Nov 2020, prospective, India, peer-reviewed, 13 authors, trial NCT04408456 (history).
This PaperHCQAll
Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study
Deba Prasad Dhibar, Navneet Arora, Arpit Kakkar, Neeraj Singla, Ritin Mohindra, Vikas Suri, Ashish Bhalla, Navneet Sharma, Mini P Singh, Ajay Prakash, Lakshmi Pvm, Bikash Medhi
International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106224
Many drugs have been tried for the treatment/prevention of COVID-19 with limited success. Direct household contacts of COVID-19 patients are at highest risk for SARS-CoV-2 infection. Hydroxychloroquine (HCQ) has been tried against COVID-19 owing to its in vitro virucidal action against SARS-CoV-2, but the role of HCQ as post-exposure prophylaxis (PEP) remains inconclusive. In this open-label, controlled clinical trial, asymptomatic individuals who had direct contact with laboratory-confirmed COVID-19 cases or had undertaken international travel in the last 2 weeks were offered HCQ prophylaxis and assigned to PEP ( n = 132) or control ( n = 185) group. The PEP group received HCQ 800 mg on Day 1 followed by 400 mg once weekly for 3 weeks. Both groups undertook home quarantine for 2 weeks along with social distancing and personal hygiene. Over 4-week follow-up, 50/317 participants (15.8%) had new-onset COVID-19. The incidence of COVID-19 was significantly ( P = 0.033) lower in the PEP (14/132; 10.6%) compared to the control (36/185; 19.5%) group (total absolute risk reduction, -8.9% points). The NNT to prevent the occurrence of 1 COVID-19 case was 12. Overall relative risk was 0.59 (95% CI 0.33-1.05). Compliance was good. The most common adverse event was epigastric discomfort with burning sensation (three participants), with no serious adverse events. PEP with HCQ has the potential for the prevention of COVID-19 in at-risk individuals. Until definitive therapy is available, continuing PEP with HCQ may be considered in suitable at-risk individuals. Further randomised clinical trials with larger samples are required for better evaluation of HCQ as PEP for COVID-19 prevention.
References
Anglemyer, Horvath, Bero, Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials, Cochrane Database Syst Rev, doi:10.1002/14651858.MR000034.pub2
Baden, Rubin, Covid-19-the search for effective therapy, N Engl J Med, doi:10.1056/NEJMe2005477
Biot, Daher, Chavain, Fandeur, Khalife et al., Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities, J Med Chem, doi:10.1021/jm0601856
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2016638
Catteau, Dauby, Montourcy, Bottieau, Hautekiet et al., Belgian Collaborative Group on COVID-19 Hospital Surveillance. Low-dose hydroxychloroquine therapy and mortality in hospitalized patients with COVID-19: a nationwide observational study of 8075 participants, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106144
Chatterjee, Anand, Singh, Rasaily, Singh et al., Healthcare workers & SARS-CoV-2 infection in India: a case-control investigation in the time of COVID-19, Indian J Med Res, doi:10.4103/ijmr.IJMR_2234_20
Day, Covid-19: four fifths of cases are asymptomatic, China figures indicate, BMJ, doi:10.1136/bmj.m1375
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Guan, Ni, Hu, Liang, Ou et al., China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Marmor, Kellner, Lai, Melles, Mieler, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision), Ophthalmology, doi:10.1016/j.ophtha.2016.01.058
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101738
Mygov, Government of India COVID-19 dashboard
Sarma, Kaur, Kumar, Mahendru, Avti et al., Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis, J Med Virol, doi:10.1002/jmv.25898
Sarma, Prajapat, Avti, Kaur, Kumar et al., Therapeutic options for the treatment of 2019-novel coronavirus: an evidence-based approach, J Pharmacol, doi:10.4103/ijp.IJP_119_20
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wang, Xu, Gao, Lu, Han et al., Detection of SARS-CoV-2 in different types of clinical specimens, JAMA, doi:10.1001/jama.2020.3786
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
{ 'indexed': {'date-parts': [[2024, 2, 22]], 'date-time': '2024-02-22T21:04:37Z', 'timestamp': 1708635877120}, 'reference-count': 20, 'publisher': 'Elsevier BV', 'issue': '6', 'license': [ { 'start': { 'date-parts': [[2020, 12, 1]], 'date-time': '2020-12-01T00:00:00Z', 'timestamp': 1606780800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 12]]}, 'DOI': '10.1016/j.ijantimicag.2020.106224', 'type': 'journal-article', 'created': {'date-parts': [[2020, 11, 6]], 'date-time': '2020-11-06T07:19:18Z', 'timestamp': 1604647158000}, 'page': '106224', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 13, 'title': 'Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a ' 'reality? The PEP-CQ Study', 'prefix': '10.1016', 'volume': '56', 'author': [ {'given': 'Deba Prasad', 'family': 'Dhibar', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4507-2468', 'authenticated-orcid': False, 'given': 'Navneet', 'family': 'Arora', 'sequence': 'additional', 'affiliation': []}, {'given': 'Arpit', 'family': 'Kakkar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Neeraj', 'family': 'Singla', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ritin', 'family': 'Mohindra', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vikas', 'family': 'Suri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ashish', 'family': 'Bhalla', 'sequence': 'additional', 'affiliation': []}, {'given': 'Navneet', 'family': 'Sharma', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mini P.', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ajay', 'family': 'Prakash', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lakshmi', 'family': 'PVM', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bikash', 'family': 'Medhi', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ijantimicag.2020.106224_bib0001', 'series-title': 'WHO coronavirus disease (COVID-19) dashboard', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0002', 'series-title': 'COVID-19 dashboard', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0003', 'doi-asserted-by': 'crossref', 'first-page': '1708', 'DOI': '10.1056/NEJMoa2002032', 'article-title': 'China Medical Treatment Expert Group for Covid-19. Clinical ' 'characteristics of coronavirus disease 2019 in China', 'volume': '382', 'author': 'Guan', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0004', 'doi-asserted-by': 'crossref', 'first-page': '1851', 'DOI': '10.1056/NEJMe2005477', 'article-title': 'Covid-19—the search for effective therapy', 'volume': '382', 'author': 'Baden', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.4103/ijp.IJP_119_20', 'article-title': 'Therapeutic options for the treatment of 2019-novel coronavirus: an ' 'evidence-based approach', 'volume': '52', 'author': 'Sarma', 'year': '2020', 'journal-title': 'Indian J Pharmacol'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'volume': '30', 'author': 'Wang', 'year': '2020', 'journal-title': 'Cell Res'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0007', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.105949', 'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results ' 'of an open‐label non‐randomized clinical trial', 'volume': '56', 'author': 'Gautret', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '2845', 'DOI': '10.1021/jm0601856', 'article-title': 'Design and synthesis of hydroxyferroquine derivatives with antimalarial ' 'and antiviral activities', 'volume': '49', 'author': 'Biot', 'year': '2006', 'journal-title': 'J Med Chem'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0009', 'doi-asserted-by': 'crossref', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2)', 'volume': '71', 'author': 'Yao', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0010', 'doi-asserted-by': 'crossref', 'first-page': '1386', 'DOI': '10.1016/j.ophtha.2016.01.058', 'article-title': 'American Academy of Ophthalmology. Recommendations on screening for ' 'chloroquine and hydroxychloroquine retinopathy (2016 revision)', 'volume': '123', 'author': 'Marmor', 'year': '2016', 'journal-title': 'Ophthalmology'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0011', 'series-title': 'Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 ' 'infection', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0012', 'doi-asserted-by': 'crossref', 'first-page': '517', 'DOI': '10.1056/NEJMoa2016638', 'article-title': 'A randomized trial of hydroxychloroquine as postexposure prophylaxis ' 'for Covid-19', 'volume': '383', 'author': 'Boulware', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0013', 'doi-asserted-by': 'crossref', 'first-page': '776', 'DOI': '10.1002/jmv.25898', 'article-title': 'Virological and clinical cure in COVID-19 patients treated with ' 'hydroxychloroquine: a systematic review and meta-analysis', 'volume': '92', 'author': 'Sarma', 'year': '2020', 'journal-title': 'J Med Virol'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0014', 'series-title': '‘Solidarity’ clinical trial for COVID-19 treatments', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0015', 'doi-asserted-by': 'crossref', 'first-page': 'm1375', 'DOI': '10.1136/bmj.m1375', 'article-title': 'Covid-19: four fifths of cases are asymptomatic, China figures indicate', 'volume': '369', 'author': 'Day', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0016', 'first-page': '1843', 'article-title': 'Detection of SARS-CoV-2 in different types of clinical specimens', 'volume': '323', 'author': 'Wang', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0017', 'doi-asserted-by': 'crossref', 'first-page': '459', 'DOI': '10.4103/ijmr.IJMR_2234_20', 'article-title': 'Healthcare workers & SARS-CoV-2 infection in India: a case–control ' 'investigation in the time of COVID-19', 'volume': '151', 'author': 'Chatterjee', 'year': '2020', 'journal-title': 'Indian J Med Res'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0018', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101738', 'article-title': 'Early treatment of COVID-19 patients with hydroxychloroquine and ' 'azithromycin: a retrospective analysis of 1061 cases in Marseille, ' 'France', 'volume': '35', 'author': 'Million', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106224_bib0019', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.106144', 'article-title': 'Belgian Collaborative Group on COVID-19 Hospital Surveillance. Low-dose ' 'hydroxychloroquine therapy and mortality in hospitalized patients with ' 'COVID-19: a nationwide observational study of 8075 participants', 'volume': '56', 'author': 'Catteau', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'issue': '4', 'key': '10.1016/j.ijantimicag.2020.106224_bib0020', 'article-title': 'Healthcare outcomes assessed with observational study designs compared ' 'with those assessed in randomized trials', 'author': 'Anglemyer', 'year': '2014', 'journal-title': 'Cochrane Database Syst Rev'}], 'container-title': 'International Journal of Antimicrobial Agents', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0924857920304350?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0924857920304350?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 4, 2]], 'date-time': '2022-04-02T00:31:35Z', 'timestamp': 1648859495000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0924857920304350'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 12]]}, 'references-count': 20, 'journal-issue': {'issue': '6', 'published-print': {'date-parts': [[2020, 12]]}}, 'alternative-id': ['S0924857920304350'], 'URL': 'http://dx.doi.org/10.1016/j.ijantimicag.2020.106224', 'relation': {}, 'ISSN': ['0924-8579'], 'subject': ['Pharmacology (medical)', 'Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'container-title-short': 'International Journal of Antimicrobial Agents', 'published': {'date-parts': [[2020, 12]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Post-exposure prophylaxis with hydroxychloroquine for the prevention of ' 'COVID-19, a myth or a reality? The PEP-CQ Study', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Journal of Antimicrobial Agents', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ijantimicag.2020.106224', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. ' 'All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '106224'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit